The increase in oxidative stress (and loss of antioxidative defense) is critically related to the onset of PD (Johnson et al., 2012); treatment with 6‐hydroxydopamine, in an animal model of PD, caused a reduction and elevation in the levels of SIRTI and acetylated Bmal1, respectively, causing abnormal antioxidative activity. This evidence concerns the gene BMAL1 and Parkinson disease.